Amesite Issues 696,866 Shares at $1.435 Each

Amesite announced that it has entered into definitive agreements for the purchase and sale of 696,866 shares of its common stock, at a purchase price of $1.435 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, the company has agreed to issue to the investor unregistered Series A-1 warrants to purchase up to 696,866 shares of common stock and unregistered Series A-2 warrants to purchase up to 696,866 shares of common stock. The warrants will have an exercise price of $1.435 per share and will be exercisable beginning on the effective date of stockholder approval for the issuance of the shares issuable upon exercise of the warrants. Concurrently with the registered direct offering, in a private placement priced at-the-market under Nasdaq rules, the company entered into definitive agreements with the investors for the purchase and sale of 696,866 shares of common stock, Series A-1 warrants to purchase up to 696,866 shares of the company's common stock and Series A-2 warrants to purchase up to 696,866 shares of the company's common stock at a purchase price of $1.435 per share and accompanying warrants. The warrants to be issued in the private placement will have an exercise price of $1.435 per share and will be exercisable beginning on the effective date of stockholder approval for the issuance of the shares issuable upon exercise of the warrants. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings. The offerings are expected to close on or about April 28, 2026, subject to satisfaction of customary closing conditions. The aggregate gross proceeds to the company from the offerings are expected to be approximately $2M, before deducting the placement agent's fees and other offering expenses payable by the company. The potential additional gross proceeds to the company from the warrants, if fully exercised on a cash basis, will be approximately $4M.